Literature DB >> 18758219

Proximal ureteral calculi: shock wave or ureterolithotripsy?

Renato N Pedro1, Nelson Rodrigues Netto.   

Abstract

OBJECTIVE: To compare the success rates and efficiency of ureterolithotripsy (URL) and extracorporeal shock wave lithotripsy (SWL) for proximal ureteric stones. CASUISTRY AND METHODS: A prospective non-randomized study was performed between 1999 and 2004. Of a total of 235 patients, 121 underwent SWL and 114 had ureteroscopy with ultrasonic lithotripsy. There were no significant differences between the groups. The success rate, operative time, postoperative pain and complications were analyzed in each group. Patients were followed postoperatively for a minimum of 3 months (median 6 months).
RESULTS: Treatment success rate was defined as the complete removal or as the radiographic absence of calculi at a 3-month follow-up. The URL success rate was 85.6% (98/114) and 89.5% (68/95) after one SWL session and (77/85) 90.6% after a second treatment. No differences were found in the results, overall complication rates and mean procedure time. However, the fluoroscopy time was longer in the URL group and pain was more frequent.
CONCLUSIONS: Semirigid URL is as efficient as SWL in the treatment for proximal ureteral stone. However, SWL requires less fluoroscopic time and fewer pain relievers. (c) 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2008        PMID: 18758219     DOI: 10.1159/000144060

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  2 in total

1.  Pneumatic versus laser ureteroscopic lithotripsy: a comparison of initial outcomes and cost.

Authors:  Aslan Demir; Mert Ali Karadağ; Kurşat Ceçen; Mehmet Uslu; Omer Erkam Arslan
Journal:  Int Urol Nephrol       Date:  2014-08-01       Impact factor: 2.370

2.  An alternative treatment for high-burden ureteral stones: percutaneous antegrade ureteroscopy.

Authors:  Mustafa Okan Istanbulluoglu; Mehmet Resit Goren; Tufan Cicek; Bulent Ozturk; Hakan Ozkardes
Journal:  Urol Res       Date:  2010-12-31
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.